

Unaudited Financial Results for the Quarter and Half year ended June 30, 2012																		
Particulars	Consolidated						Standalone											
	Quarter Ended			Year to date			Year ended			Quarter Ended			Year to date			Year ended		
	30th June 2012	31st March 2012	30th June 2011	30th June 2012	30th June 2011	31st December 2011	30th June 2012	31st March 2012	30th June 2011	30th June 2012	30th June 2011	31st December 2011						
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited						
PART I																		
1. Income from Operations																		
(a) Net Sales/Income from Operations (Net of excise duty)	19,487.57	18,035.03	19,167.00	37,522.61	34,832.27	73,876.57	17,987.87	15,260.86	16,690.13	33,248.73	28,639.24	64,966.75						
(b) Other Operating Income	70.15	62.40	31.54	132.55	73.75	171.68	70.15	62.40	31.54	132.55	73.75	171.68						
Total Income from operations (net)	19,557.72	18,097.43	19,198.54	37,655.16	34,906.02	74,048.25	18,058.02	15,323.26	16,721.67	33,381.28	28,712.99	65,138.43						
2. Expenses																		
a. Cost of materials consumed	4,822.96	5,821.71	5,557.92	10,644.67	11,327.74	22,865.55	4,822.96	5,821.71	5,557.92	10,644.67	11,327.74	22,865.55						
b. Purchase of stock-in-trade	859.52	1,675.30	2,090.42	2,534.82	3,820.25	5,533.43	963.70	1,509.14	1,038.81	2,472.85	2,015.56	3,706.48						
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	43.39	(143.78)	(835.02)	(100.39)	(1,681.40)	(1,287.29)	(410.37)	(453.42)	(679.93)	(863.79)	(1,143.20)	(1,222.36)						
d. Employee benefits expense	1,234.70	1,150.95	1,243.12	2,385.65	2,451.30	4,522.64	1,141.16	1,110.38	1,129.31	2,251.54	2,223.56	4,304.50						
e. Depreciation and amortisation expense	1,682.13	1,612.53	1,322.29	3,294.66	2,599.86	5,467.62	1,676.09	1,603.04	1,314.25	3,279.13	2,583.21	5,434.13						
f. Other expenses	4,824.65	4,976.55	4,706.00	9,801.20	8,609.16	18,656.57	4,822.23	4,639.00	4,558.05	9,406.84	8,287.76	17,297.14						
Total Expenses	13,467.35	15,093.26	14,084.73	28,560.61	27,126.91	55,758.51	13,015.77	14,229.85	12,918.41	27,191.25	25,294.63	52,385.43						
3. Profit / (Loss) from Operations before Other Income, finance costs and exceptional Items (1-2)	6,090.37	3,004.17	5,113.81	9,094.55	7,779.12	18,289.74	5,042.25	1,093.41	3,803.26	6,190.03	3,418.36	12,753.00						
4. Other Income																		
5. Profit / (Loss) from ordinary activities before finance costs and exceptional Items (3+4)	63.20	676.84	457.91	740.04	1,064.59	1,709.67	376.24	580.29	457.91	902.14	1,064.61	1,592.30						
5. Profit / (Loss) from ordinary activities before finance costs and exceptional Items (3+4)	6,153.57	3,681.01	5,571.72	9,834.59	8,843.71	19,999.41	5,418.49	1,673.70	4,261.17	7,092.17	4,482.97	14,345.30						
6. Finance Costs																		
7. Profit / (Loss) from ordinary activities after finance costs but before exceptional Items (5-6)	1,680.14	1,487.80	1,128.86	3,167.94	2,223.36	4,853.77	1,680.10	1,487.78	1,128.82	3,167.88	2,223.31	4,853.77						
7. Profit / (Loss) from ordinary activities after finance costs but before exceptional Items (5-6)	4,473.43	2,193.21	4,442.86	6,666.65	6,620.35	15,145.65	3,738.39	185.92	3,132.35	3,924.29	2,259.66	9,491.53						
8. Exceptional Items																		
9. Profit / (Loss) from Ordinary Activities before tax (7+8)	-	-	-	-	-	-	-	-	-	-	-	-						
9. Profit / (Loss) from Ordinary Activities before tax (7+8)	4,473.43	2,193.21	4,442.86	6,666.65	6,620.35	15,145.65	3,738.39	185.92	3,132.35	3,924.29	2,259.66	9,491.53						
10. Tax expense																		
a. Current Tax	1,053.92	63.86	887.43	1,117.78	888.04	2,153.66	1,053.92	63.86	880.00	1,117.78	880.00	2,150.00						
b. MAT Credit Entitlement	-	-	-	-	(505.89)	(594.84)	-	-	-	-	(505.89)	(594.84)						
c. Deferred Tax	186.97	(83.28)	(216.58)	103.69	(272.93)	800.38	186.97	(83.28)	(216.58)	103.69	(272.93)	800.15						
d. Short / (Excess) Provision of Tax in Earlier Periods	-	44.06	-	44.06	750.00	160.90	-	44.06	-	44.06	750.00	160.90						
Total Tax Expense	1,240.89	24.64	670.85	1,265.53	859.22	2,520.10	1,240.89	24.64	663.42	1,265.53	851.18	2,516.21						
11. Net Profit / (Loss) from Ordinary Activities after tax (9-10)	3,232.52	2,168.57	3,772.01	5,401.12	5,761.13	12,625.55	2,497.50	161.28	2,468.93	2,658.76	1,408.48	6,975.32						
12. Extraordinary Item																		
13. Net Profit / (Loss) for the period (11-12)	-	-	-	-	-	98,829.51	-	-	-	-	-	81,280.91						
13. Net Profit / (Loss) for the period (11-12)	3,232.52	2,168.57	3,772.01	5,401.12	5,761.13	12,625.55	2,497.50	161.28	2,468.93	2,658.76	1,408.48	6,975.32						
14. Share of profit / (loss) of associates																		
15. Minority interest																		
16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates																		
17. Paid-up equity share capital (Face Value - Rs. 10/- Per Share)																		
18. Reserve excluding Revaluation Reserves (As per Balance Sheet of previous accounting year)	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78						
19. Basic and Diluted Earnings Per Share (EPS) (before & after extraordinary items) (of Rs. 10/- each) (Not Annualised)	5.07	3.40	5.91	8.46	9.03	19.78	3.91	0.25	3.87	4.17	2.21	10.93						
See accompanying note to the financial results																		
PART II																		
A PARTICULARS OF SHAREHOLDING																		
1. Public Shareholding																		
- No. of shares	20,883,459	19,783,459	19,783,459	20,883,459	19,783,459	19,783,459	20,883,459	19,783,459	19,783,459	20,883,459	19,783,459	19,783,459						
- Percentage of shareholding	32.72%	31.00%	31.00%	32.72%	31.00%	31.00%	32.72%	31.00%	31.00%	32.72%	31.00%	31.00%						
2. Promoters and Promoter group shareholding																		
a) Pledged/Encumbered																		
- Number of shares	9,154,930	9,154,930	-	9,154,930	-	10,053,120	9,154,930	9,154,930	-	9,154,930	-	10,053,120						
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	21.32%	20.79%	-	21.32%	-	22.83%	21.32%	20.79%	-	21.32%	-	22.83%						
- Percentage of shares (as a % of the total share capital of the Company)	14.35%	14.35%	-	14.35%	-	15.75%	14.35%	14.35%	-	14.35%	-	15.75%						
b) Non-encumbered																		
- Number of Shares	33,779,376	34,879,376	44,034,306	33,779,376	44,034,306	33,981,186	33,779,376	34,879,376	44,034,306	33,779,376	44,034,306	33,981,186						
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	78.68%	79.21%	100%	78.68%	100%	77.17%	78.68%	79.21%	100%	78.68%	100%	77.17%						
- Percentage of shares (as a % of the total share capital of the Company)	52.93%	54.65%	69%	52.93%	69%	53.25%	52.93%	54.65%	69%	52.93%	69%	53.25%						
B INVESTOR COMPLAINTS																		
Pending at the beginning of the quarter												-						
Received during the quarter												9						
Disposed of during the quarter												9						
Remaining unresolved at the end of the quarter												-						

Notes:

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9th August, 2012
The Statutory Auditors have carried out a Limited Review of the unaudited financial results for the quarter and half year ended on 30th June.2012.

2 The initial public offer (IPO) proceeds have been utilised as per the objects of the issue as approved by the Shareholders.

A) The Utilisation of Issue Proceeds from IPO is as follows

(Rs.in Lacs)

Particulars of Fund utilisation for	Amount to be utilised as per Prospectus / Shareholders Approval				Amount utilised		
	Total	Year 2010	Year 2011	Year 2012	Upto 31st Dec 2010	Upto 31st Dec 2011	Upto 30th June 2012
Setting up of a new project in existing facility.....	13,464.80	3,750.70	7,023.80	2,690.30	-	10,669.06	11,887.07
Towards Research and Development activities	1,450.00	663.60	786.40	-	-	1,450.00	1,450.00
Repayment of Term Loans.....	9,321.40	4,591.40	4,730.00	-	4,591.40	4,591.40	6,683.98
General Corporate Purposes	3,190.00	-	3,190.00	-	-	3,042.47	3,042.47
Issue Expenses	2,573.80	2,573.80	-	-	1,747.71	2,573.80	2,573.80
Total	30,000.00	11,579.50	15,730.20	2,690.30	6,339.11	22,326.73	25,637.32
B) The unutilised proceeds are							
held in fixed deposits accounts					23,071.73	5,949.38	4,236.64
held in Escrow Account					589.16	-	-
used towards paying down working capital / short term credit limits / in current account.....					-	1,723.89	126.04
Total					30,000.00	30,000.00	30,000.00

3 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.

4 Statement of Assets and Liabilities

(Rs. In Lacs)

Particulars	Consolidated		Standalone	
	As at 30th June 2012	As at 31st December 2011	As at 30th June 2012	As at 31st December 2011
	Unaudited	Audited	Unaudited	Audited
A. EQUITY AND LIABILITIES				
1. Shareholders' Funds:				
Share Capital	6,381.78	6,381.78	6,381.78	6,381.78
Reserves and Surplus	105346.03	98829.53	83,939.67	81,280.91
Sub-total - Shareholders' funds	111,727.81	105,211.31	90,321.45	87,662.69
2. Minority Interest	-	-	-	-
3. Non - current liabilities				
Long-term borrowings	25651.89	18172.20	25,651.89	18,172.20
Deferred tax liabilities (net)	6117.54	6012.27	6,128.14	6,024.44
Long-term provisions	780.50	742.03	743.53	704.65
Sub-total - Non-current liabilities	32,549.93	24,926.50	32,523.56	24,901.29
4. Current liabilities				
Short-term borrowings	18,588.35	18,949.18	18,588.35	18,949.18
Trade payables	7092.32	6471.55	6,633.77	5,911.62
Other current liabilities	19868.44	14953.08	21,958.37	17,049.37
Short-term provisions	977.34	2549.53	1,032.17	2,509.35
Sub-total - Current liabilities	46,526.45	42,923.34	48,212.66	44,419.52
TOTAL - EQUITY AND LIABILITIES	190,804.19	173,061.15	171,057.67	156,983.50
B. ASSETS				
1. Non - current assets				
Fixed assets	95297.41	77007.78	88,290.16	70,345.47
Goodwill on Consolidation	3.20	3.20	-	-
Non - current investments	1.94	1.94	1,705.72	1,705.72
Long-term loans and advances	16670.43	19593.67	16,500.90	19,426.09
Sub-total - Non-current assets	111,972.98	96,606.59	106,496.78	91,477.28
2. Current assets				
Inventories	17064.12	16896.25	16,142.03	15,210.76
Trade receivables	27834.08	27396.59	21,495.87	24,385.62
Cash and cash equivalents	17339.30	15933.66	16,588.51	15,293.12
Short -term loans and advances	16228.92	16097.44	9,969.69	10,486.10
Other current assets	364.79	130.62	364.79	130.62
Sub-total - Current assets	78,831.21	76,454.56	64,560.89	65,506.22
TOTAL - ASSETS	190,804.19	173,061.15	171,057.67	156,983.50

5 The figures for the previous year / period have been regrouped / rearranged wherever necessary.

For Claris Lifesciences Ltd